Novartis has announced the results of a new post-hoc analysis in a subgroup of patients with heart failure with reduced ejection fraction (IC-FER) and diabetes that suggest that Sacubitril/Valartan tablets, marketed with the name of entertainment, improveThe glycemic control, evaluated according to the A1C (HBA1C) hemoglobin test, compared to the ECA ENALAPRIL inhibitor.
The IC-FER is also known as systolic heart failure (IC).This medicine is indicated to reduce the risk of cardiovascular death and hospitalization by IC in patients with chronic IC (NYHA class II-IV) and reduced ejection fraction.It is not indicated to treat diabetes.
"The drug can have important metabolic benefits for patients with IC-FER with diabetes" the drug reduced HBA1C levels, a measure of the average blood glucose levels during the last two to three months, after a year ofTreatment for IC, and this effect was maintained during the three years of follow -up of the study.
In the analysis, the new use of insulin therapy or oral diabetic agents was also reduced in the entertainment group.The findings come from the data of Paradigm-HF, the largest clinical trial in IC, which have been presented simultaneously in the 66th annual scientific session and Expo of the American College of Cardiology (ACC) in Washington, DC and are published in TheLancet Diabetes & AMP;Endocrinology.
"Diabetes is an important risk factor in heart failure and is closely related to the progression of the disease, which places patients with heart failure at a greater risk of hospitalization and death," explains Scott Solomon, MD, director ofNon -invasive cardiology, Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School, and one of the authors of the publication.
"This analysis suggests that, in addition to the benefits in heart failure demonstrated in the paradigm-HF, the medicine can also help maintain glycemic control among patients with heart failure with diabetes."
"These results show that in addition to their convincing cardiovascular efficiency, the drug may have important metabolic benefits for patients with IC-FER with diabetes," says Vasant Narasimhan, Global Head, Drug Development and Chief Medical Navartis.
"We are excited about these results and we are committed to improving our understanding of the benefits of entertainment in the different populations of patients with heart failure."